Augmentation of antitumor effect by combined administration with interleukin-2 and sizofiran, a single glucan, on murine EL-4 lymphoma

Biotherapy

Volumn 9, Issue 4, 1996, Pages 241-247

  Kano, Yuji ^a,b   Kakuta, Hiroyuki ^a   Hashimoto, Junichi ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor effect; Combination therapy; EL 4 lymphoma; Recombinant human interleukin 2 (rIL 2); Sizofiran (SPG)

Indexed keywords

CELL SURFACE MARKER; GLUCAN; IMUNACE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; SCHIZOPHYLLAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; IMMUNE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOMA; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; SCHIZOPHYLLUM COMMUNE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; T LYMPHOCYTE;

EID: 0030452880     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02620737     Document Type: Article

References (12)

1. Chen JT, Hasumi K. Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-gamma. Biotherapy 1993; 6: 189-94.
2. Chose T, Guclu A, Tai J, Mammen M, Norvell ST. Immunoprophylaxis and immunotherapy of EL4 lymphoma. Europ. J. Cancer 1977; 13: 925-935.
3. Ota T, Tanino M, Kohno H, Funamoto H, Odashima S. Isolation and Characterization of a low metastatic variant from EL-4 mouse T-lymphoma. Clin. Exp. Metastasis 1992; 10: 297-308.
4. Gillis S, Perm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 1978; 120: 2027-2032.
5. Stadler BM, Dougherty SF, Farrar JJ, Oppenheim JJ. Relationship of cell cycle to recovery of IL-2 activity from human mononuclear cells, human and mouse T cell Unes. J. Immunol. 1981; 127: 1936-1940.
6. Morgan DA, Rusetti FW, Gallo RC. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1976; 192:1007-8.
7. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocyte. J Exp Med 1982; 155: 1823-41.
8. Sugawara I, Lee KC, Wong M. Schizophyllan(SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells: [.Characteristics of SPG-treated macrophages. Cancer Immunol Immunother 1984; 16: 13744.
9. Tsuchiya Y, Yamamoto M, Igarashi M, Suzuki R, Kumagai K. Study on immunomodulating activity of an antitumor glucan, sizofiran at tumoral factor level. Clin Immunol 1986; 18: 57584.
10. Tsuchiya Y, Igarashi M, Inoue M, Kumagai K. Cytokinerelated immunomodulating activities of an anti-tumor glucan, sizoflran (SPG). J Pharmacobio-Dyn 1989; 12: 616-25.
11. Ho RL, Maccubbin DL, Ujhaezy P, Zaleskis G, Eppolito C, Mihich E, Ehrke MJ. Immunological Responses Critical to the Therapeutic Effects of Adriamycin Plus Interleukin 2 in C57BL/6 Mice bearing syngeneic EL-4 Lymphoma. Oncol Res 1993; 5: 363-72.
12. Hanna N, Fidler U. Role of natural killer cells in the destruction of circulating tumor emboli. J. natn. Cancer Inst. 1980; 65: 801-9.